Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


08. June 2020 | 11:30 CET

Aurora, Bayer, XPhyto - scalable growth markets with potential

  • Health
Photo credits: pixabay.com

Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and therapies. The development of new markets and preparations usually requires a lot of risk capital before the fruits can be harvested. At the latest when a scalable solution has been found to improve people's lives, then the value of the company increases.

time to read: 1 minutes by Mario Hose
ISIN: CA98421R1055 , CA05156X8843 , DE000BAY0017


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Patches to treat diseases

The Canadian company XPhyto Therapeutics Corp. announced this morning that its wholly owned German subsidiary, Vektor Pharma TF GmbH, has completed the formula for its novel transdermal delivery system for the neurological drug Rotigotine. Vektor is now proceeding with the process implementation for the production of Rotigotine patches for human clinical trials.

The active ingredient Rotigotine is a generic and off-patent drug and is used for the treatment of Parkinson's disease and restless legs syndrome in Europe and the United States. The global market for Rotigotine patches was worth approximately CAD 250 million to CAD 500 million in 2019.

Results expected in 2020

"We are extremely pleased with the TDS development results thus far. It appears that our goal of optimizing the dosage form efficiency, to reduce the amount of drug required in each patch, and improving overall patch adhesion to the patient's skin has been achieved," said Prof. Dr. Thomas Beckert, founder and managing director of Vektor.

Once process implementation is complete, clinical sample manufacturing and analytical work will commence in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany. Human pilot studies in Europe are scheduled for Q3 2020 with results expected in Q4 2020, according to today's announcement.

Newcomers with potential

The market value of XPhyto at the current share price level of EUR 2.11 is approximately EUR 116 million. Compared to other companies dealing with the topic of health the value is still low and at the same time expresses the potential. Aurora Cannabis has a market value of EUR 1.39 billion at a share price of EUR 12.57. With a market capitalisation of EUR 64.99 billion and a share price of EUR 66.62, the pharmaceutical giant Bayer is a heavyweight.

Usually every company starts small and XPhyto is positioned in promising and scalable growth markets with its German subsidiaries Bunker Pflanzenextrakte GmbH and Vektor Pharma TF GmbH.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

09. February 2021 | 08:00 CET | by Stefan Feulner

CureVac, Cardiol Therapeutics, Bayer - roaring profits!

  • Health

The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.

Read

08. February 2021 | 07:30 CET | by Nico Popp

Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here

  • Health

Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.

Read

28. January 2021 | 10:39 CET | by André Will-Laudien

Fresenius - Q&M Dental Group - IBU-tec: New price explosions every day!

  • Health

Rarely has the stock market been so volatile and exciting as in the last few days. Hedge fund Melvin Capital had to close out because of the GameStop share, and now the next wave is probably looming with AMC Entertainment. A full 270% went through the roof right at the opening; according to the New York Stock Exchange (NYSE) thousands of buy orders were already there at opening. Again, there had been a recommendation in a social media channel. On the Nasdaq, it jumped rapidly from USD 5 to USD 21 right at the opening - something you rarely see. And GameStop continues today after yesterday's debacle! After several trading suspensions, the value exploded further from USD 149 to USD 380 after a good hour of trading. That should have been the end of trading school for many new entrants!

Read